Trial Details

Recruiting
Basic Information
Clinical ID c4967
Identifier ISRCTN95420128
Trial Title Subcutaneous CT-P13 monotherapy versus combination with immunomodulation when switching from intravenous infliximab in inflammatory bowel disease A multicentre, randomised withdrawal trial
Trial URL Visit Original Page
Study Information
Study Results

Yes

Conditions Crohn's disease and ulcerative colitis Digestive System
Interventions The intervention is the withdrawal of immunomodulators (azathioprine or mercaptopurine) in IBD patients switching from IV infliximab to subcutaneous infliximab (SC CT-P13). Participants will be randomised 1:1 to either continue or discontinue immunomodul
Participant Information
Sponsor Kings Health Partners
City NULL
Country/Region United Kingdom
Enrollment Criteria
Sex Requirement ALL
Age Requirement NULL
Study Design
Study Type Interventional
Phase PHASE4
Time Information
Start Date NULL
Primary Completion Date NULL
Completion Date NULL